The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.

Bristol Myers is making waves after a period of pressure. The stock jumped 6.3% recently, outperforming its industry and the ...

Johnson & Johnson eyes FDA nod to icotrokinra after phase III studies show strong skin clearance and safety in plaque ...

Sotyktu (deucravacitinib) has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026.

US FDA accepts Bristol Myers Squibb’s sNDA for Sotyktu to treat adults with active psoriatic arthritis: Princeton, New Jersey Tuesday, July 22, 2025, 12:00 Hrs [IST] Bristol Mye ...

The US Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis ...

Icotrokinra is a first-in-class targeted oral peptide that blocks interleukin (IL) 23 and its receptor, which plays a key ...

Upset that “pornographic” novels were in public school libraries, state leaders demanded administrators remove 55 books from their shelves, and Orange County Public Schools complied last month. But ...

SpaceX has lined up an evening launch from Cape Canaveral on Monday, but the threat of thunderstorms could force a delay.

Domino’s reported better-than-expected second-quarter US sales, with new menu items ...

Bristol Myers Squibb said the U.S. Food and Drug Administration has accepted its application seeking expanded approval of its plaque psoriasis drug Sotyktu for the treatment of adults with active ...

Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main ...